VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing

Reuters

2025/07/17

VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing

VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC Voyager Acquisition Corp. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a "crossover" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2170940_de), on July 17, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2552108820"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552108820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552108820?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 13:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552108820","market":"us","top_or_hot":-1,"title":"VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC <a href=\"https://laohu8.com/S/VACH\">Voyager Acquisition Corp</a>. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a \"crossover\" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2170940_de), on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 13:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC <a href=\"https://laohu8.com/S/VACH\">Voyager Acquisition Corp</a>. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a \"crossover\" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2170940_de), on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VACH","symbol_name":"Voyager Acquisition Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL2JYngT:1","article_id":"2552108820","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552108820","pubTimestamp":1752728479,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus  with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC Voyager Acquisition Corp. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a \"crossover\" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VACH":"Voyager Acquisition Corp"},"translate_title":"Xlife Sciences AG子公司VERAXA Biotech AG提交F-4纳斯达克上市申请，达到重要里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VACH":0.9},"content_text":"VERAXA Biotech AG, a Subsidiary of Xlife Sciences AG, Reaches Key Milestone with F-4 Filing for NASDAQ Listing\n    \n\n        VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has made significant strides towards its NASDAQ listing with the filing of a prospectus (F-4 Filing) with the U.S. Securities and Exchange Commission. This registration statement includes essential details about the planned business combination with NASDAQ-listed SPAC Voyager Acquisition Corp. The transaction is valued at approximately $1.3 billion, with VERAXA shareholders set to receive around 130 million shares of the merged entity. The anticipated pro-forma market capitalization post-merger is approximately $1.64 billion, assuming a share price of $10.00. VERAXA is also conducting a \"crossover\" financing round expected to conclude before the merger's completion, targeted for the fourth quarter of 2025. This development underscores VERAXA's progress in oncology therapies and aligns with Xlife Sciences' strategy of merging academic innovation with market-driven commercialization.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2170940_de), on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}